nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-2603CDF0·Framework v5.8·Pipeline v0.4·Evaluated 19 Aug 2026·OECD: 3.1 Basic medicine·Subfield: Molecular Biology·Basis: Full text·Type: Laboratory experiment

Intestinal epithelial cell-specific restoration of Nrf2 gene in whole-body-knockout mice ameliorates acute colitis.

Sato et al.Sato, To, Sakurai et al.·2025·Experimental animals·10.1538/expanim.24-0152 ↗

Primary claim

IEC-specific expression of Nrf2 ameliorated DSS-induced acute colitis.

Supported · convergent acute clinical and histological rescue, tempered by unadjusted multiple testing
In brief

A targeted genetic rescue clarifies Nrf2’s acute epithelial protection in DSS colitis, but uncorrected multiple testing limits confidence in secondary findings.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Unbalanced redox homeostasis leads to the production of reactive oxygen species and exacerbates inflammatory bowel disease. To investigate the role of the transcription factor Nrf2, a major antioxidative stress sensor, in intestinal epithelial cells (IECs), we generated IEC-specific Nrf2 gene knock-in mice (Nrf2-vRes), which express Nrf2 only in IECs, using the cre/loxp system. Colitis was induced in wild-type (WT) mice, whole-body Nrf2-knockout (Nrf2-KO) mice, and Nrf2-vRes mice by administering dextran sulfate sodium (DSS) for 1 week (acute model) or intermittently for 5 weeks (chronic model). The mRNA and protein levels of NAD(P)H:quinone oxidoreductase 1 (NQO1), which is involved in the oxidative stress response in a manner regulated by Nrf2, were reduced in Nrf2-KO compared with those in WT, while these decreases were reversed in Nrf2-vRes at all timepoints. Nrf2-KO mice administered DSS developed more severe colitis with higher disease activity index, higher leucine-rich α2 glycoprotein in serum, shorter colon length, and more severe epithelial damage and infiltration of inflammatory cells histopathologically than did WT mice in the acute model; moreover, these exacerbations of colitis were ameliorated in Nrf2-vRes mice. However, these differences were not observed among the three sets of mice in the chronic model. IEC-specific expression of Nrf2 ameliorated DSS-induced acute colitis. These results suggest that Nrf2 expression in IECs plays a protective role against early-stage colitis and undertakes important regulatory functions during intestinal inflammation.

Key Claims

Primary finding · Supported

IEC-specific expression of Nrf2 ameliorated DSS-induced acute colitis.

Possible — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

convergent acute clinical and histological rescue, tempered by unadjusted multiple testing

Abstract; Results, Figures 2–4; Conclusion
Quote verified
Secondary · Supported

These results suggest that Nrf2 expression in IECs plays a protective role against early-stage colitis and undertakes important regulatory functions during intestinal inflammation.

single male-mouse DSS model limits the broader inflammatory-regulation inference

Abstract; Conclusion
Quote verified
Secondary · Supported

the ameliorative effect of Nrf2 in IECs against DSS-induced colitis was not as prominent in the chronic models

consistent chronic null findings within an acknowledged imperfect chronic DSS model

Discussion, paragraph 4; Abstract; Results, Figures 2–3
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Targeted rescue isolates epithelial Nrf2

Restoring Nrf2 specifically in IECs on a whole-body knockout background provides a direct comparison with WT and knockout controls while avoiding the supraphysiological overexpression central to prior contradictory work.

↳ Introduction, final paragraph; Materials and Methods, Animals; Figure 1

#methodological rigour

Convergent acute-colitis outcome measures

DAI, serum LRG, colon length, and blinded histopathological scores consistently show worse acute disease in Nrf2-KO mice and improvement in Nrf2-vRes mice.

↳ Results, Figures 2–3

#positioning

Null and contradictory evidence remains visible

The paper reports the chronic-model null findings and non-significant IHC results, while the Discussion directly engages prior evidence that epithelial Nrf2 overexpression aggravated colitis.

↳ Abstract; Results, Figures 2–3 and 6; Discussion, paragraph 2

Limitations

#methodological rigour

Multiplicity control is not reported

Figures 2–6 contain numerous pairwise genotype, timepoint, and outcome comparisons, but the Statistical Analysis section reports unpaired t-tests without a stated multiplicity adjustment. This raises false-positive risk for individual secondary findings.

↳ Materials and Methods, Statistical Analysis; Figures 2–6

#methodological rigour

Protein evidence has very small samples

The NQO1 and HEL immunoblot quantification uses n=3 per group, limiting confidence in the protein-level and oxidative-stress findings.

↳ Results, Figure 5

#application pathway

Transferability remains narrowly tested

The experiments use male C57BL/6-background mice and a single DSS framework, without alternate colitis models, female cohorts, pharmacological targeting, or human validation.

↳ Materials and Methods, Animals; Figure 1C

Does this match your read? Add your assessment ↓

Nabu Commentary

The genetic rescue design is appropriately targeted to the question of whether physiological Nrf2 expression in IECs protects against DSS colitis. Acute effects converge across DAI, LRG, colon length, and blinded histology, while the chronic null findings are reported clearly. The principal analytical constraint is the use of repeated pairwise t-tests across many outcomes and timepoints without a stated multiplicity correction, compounded by n=3 immunoblot quantification. The result is a credible mechanistic clarification whose secondary molecular findings and broader translational implications require cautious interpretation.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.6±0.1

Contribution
3.7

The IEC-specific rescue on a whole-body knockout background directly addresses the conflict between prior knockout and overexpression findings. The advance is meaningful but remains an incremental mechanistic clarification in one animal model.

Introduction, final paragraph; Discussion, paragraphs 1–2

“IEC-specific expression of Nrf2 ameliorated DSS-induced colitis in the early phase.”

Methodological Rigour
3.5

The three-genotype acute/chronic design, baseline model validation, and blinded histological scoring fit the causal question. Pairwise t-tests across numerous comparisons, immunoblot n=3, and the absence of a power calculation limit analytical confidence.

Figure 1; Histological Analysis; Statistical Analysis; Figure 5

“The significance of differences was evaluated using a two-tailed unpaired Student’s t-test when two groups were compared.”

Reporting
3.7

The paper maintains a coherent progression from the disputed IEC role to genetic rescue, acute benefit, and chronic null findings. Conclusions are generally calibrated, although the phrase “important regulatory functions” is broader than the directly demonstrated phenotype.

Abstract; Results headings; Discussion; Conclusion

“However, these differences were not observed among the three sets of mice in the chronic model.”

Positioning
3.7

The discussion directly addresses the contradictory Nrf2-overexpression study and distinguishes physiological restoration from overexpression. It traces the HEL proxy and chronic-model limitations into interpretation but does not discuss the multiplicity limitation.

Discussion, paragraphs 2–4 and Limitations paragraph

“IEC- and myeloid cell-specific overexpression of Nrf2 was reported to aggravate DSS-induced colitis.”

Lower confidence on Methodological Rigour, Positioning — domain match limited.

Reliability

Caveats4 of 4 checks


Internal CoherenceNoted

The reported findings are internally consistent, but the analysis strategy creates an elevated false-positive risk for individual outcomes. This affects confidence rather than demonstrating contradiction or integrity failure.

Research ConductClean

Animal ethics approval is declared with an identifier, and funding is reported. No explicit COI or data-availability statement appears in the supplied text, but those absences are treated as assessability gaps rather than conduct concerns.

Flags: 1 declared / 5 total

Reference IntegrityNoted

4 of 4 checkable references verified

27 references in manuscript 23 could not be checked — not the same as no match found

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Oral and gastrointestinal · Inflammatory bowel disease
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesSmall
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessControlled
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The protective effect of IEC-specific Nrf2 was demonstrated only in controlled dextran sulfate sodium mouse models of colitis, with no human or clinical evidence.

From the paper
“the regulation of Nrf2 in IECs may lead to the control of intestinal inflammatory diseases including IBD”

The paper names a possible real-world use, controlling intestinal inflammatory diseases and developing IBD treatments, but does not name who would act on the findings.

Pathway

IBD drug developers and researchers could act on these findings to design Nrf2-targeting epithelial therapies, such as optimized Nrf2 activators, for early-stage inflammatory bowel disease.

Barrier

The evidence comes from a DSS mouse model with acute-versus-chronic discrepancies, and translation to human IBD requires clinical testing of Nrf2 modulation in patients.

Evaluated 12 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Personalized redox medicine in inflammatory bowel diseases: an emerging role for HIF-1α and NRF2 as therapeutic targets

    Arno R. Bourgonje, Damian Klóska, Anna Grochot‐Przeczek, et al. · 2023 · Clinical medicine

    Evidence Score
    3.4±0.2
    Reliability
    No concerns
  2. A Protective Role of the NRF2-Keap1 Pathway in Maintaining Intestinal Barrier Function

    Zhiyong Wen, Weihua Liu, Xing Li, et al. · 2019 · Basic medicine

    Primary claim

    NRF2 reduced intestinal mucosal injury by suppressing oxidative stress

    Supported
    Evidence Score
    2.6±0.2
    Reliability
    Caveats
  3. The NRF2/Keap1 pathway as a therapeutic target in inflammatory bowel disease

    Sem Geertsema, Arno R. Bourgonje, Raphael R. Fagundes, et al. · 2023 · Clinical medicine

    Primary claim

    Preclinical evidence supports targeted therapeutic modulation of the NRF2/Keap1 pathway in the gastrointestinal tract, albeit human evidence is scarce.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    No concerns

How the rubric works →